NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
Key Financial Performance
Revenue $2.81 million, an increase of 121% year-over-year compared to $1.27 million for Q1 2024, primarily due to sales growth in both contract manufacturing and branded products.
Cost of Revenues $1.62 million, compared to $1.1 million for Q1 2024, aligned with the increase in revenue growth.
Gross Profit $1.19 million, compared to $0.16 million for Q1 2024, with a gross profit margin of 42.4% compared to 12.6% for Q1 2024, primarily due to the increase in overall sales.
Selling, General and Administrative Expenses $1.96 million, compared to $1.03 million for Q1 2024, attributable to increases in compensation and benefits, share-based compensation, advertising, marketing, Amazon fees, professional and consulting fees, and other fees.
EBITDA Negative $0.54 million, compared to negative $0.84 million for Q1 2024, reflecting improved operational performance.
Adjusted EBITDA Negative $0.47 million, compared to negative $0.73 million for Q1 2024, indicating a narrowing loss.
Net Loss $0.71 million, compared to a net loss of $0.85 million for Q1 2024, showing an improvement in net loss.
Cash Balance Approximately $1.19 million as of March 31, 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: Medagel will expand its product line with the anticipated launch of several new offerings, including the SilverSeal wound and burn kit and its moist burn pads. Kenkoderm will double the size of its product portfolio in the third quarter of 2025 with the launch of new products for eczema. Silly George will launch complementary beauty products, including five shades of lip gloss, a hydrating lip mask, and undereye patches featuring proprietary hydrogel technology.
Market Expansion: Received approval from Health Canada to sell SilverSeal in that territory. Partnership with STADA is expanding beyond Histasolv, with plans to launch another product in Q4 2025.
Operational Efficiency: Gross margins normalized to 42.4%, aligning with historical ranges. Contract manufacturing revenue increased 58% year-over-year. Consumer branded products increased 189% year-over-year, led by Silly George.
Strategic Shift: Exploring the possibility to use a new clean room in Texas for assembly to mitigate tariff impacts. Focus on driving innovation and growth across key business segments to deliver long-term value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The launch of AbbVie's RESONIC machine has been delayed due to manufacturing issues unrelated to NEXGEL, which may impact revenue opportunities.
Supply Chain Challenges: Potential tariff increases on products sourced from China could affect costs, particularly if tariffs rise from 34% to 145%. NEXGEL is monitoring this situation closely and may need to adjust its supply chain strategy.
Competitive Pressures: Increased interest in U.S.-made gels may provide a competitive advantage, but the company must remain vigilant about cheaper alternatives from abroad.
Economic Factors: The overall economic environment and potential fluctuations in consumer demand could impact revenue projections and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Contract Manufacturing Growth: Contract manufacturing revenue increased 58% year-over-year, driven by demand from existing customers and onboarding of new global corporations.
Consumer Branded Products Growth: Consumer branded products revenue increased 189% year-over-year, led by the addition of Silly George.
New Product Launches: Medagel will launch new offerings including SilverSeal wound and burn kit and moist burn pads. Kenkoderm will double its product portfolio in Q3 2025.
Partnerships: Partnership with STADA is expanding, with plans to launch another product in Q4 2025 and several more in 2026.
FDA Study: A 30-patient human trial for hydrogel efficacy in laser hair removal is complete, awaiting publication.
Revenue Guidance: The company maintains its revenue guidance of $13 million for 2025.
Cash Flow Positivity: NEXGEL expects to achieve cash flow positivity in 2025.
Gross Margin Outlook: Gross margins normalized to 42.4%, aligning with historical ranges.
Future Opportunities: The company has a robust pipeline of new customers and applications for hydrogels, indicating potential for continued growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: NEXGEL has not announced any share buyback program or dividend program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:On your guidance, how much did you bake into revenue or sales from AbbVie’s advice and does the delay affect the guidance?
A:We did not bake in a lot for AbbVie only because it’s not something that’s under our control. The revenue we had for AbbVie was relatively minor, so it should not be impactful to us meeting our projection of $13 million.
Q:Can you provide more details on the product launched with STADA in 4Q?
A:The first product was Histasolv, a digestive enzyme. The strategy with STADA is to create a line of digestive enzymes for other indications, with another product launching in Q4 and a third in Q1.
Q:Is profit still growing or are you seeing any plateauing of sales?
A:We’ve seen nothing but growth. Last month was the largest month we had on the product, and it continues to grow every month.
Q:If the tariffs end up being higher, would that impact any of your other business lines?
A:We have room to transition manufacturing to Texas if needed, but currently, the tariffs have come down to a manageable level.
Q:Would you have to hire additional people if you transition manufacturing to Texas?
A:Yes, you would need additional labor for assembly, but it’s a work in progress and we are considering different scenarios.
Q:Are there further optimizations you can make to the Silly George brand?
A:The brand is definitely going to continue to grow margins, and we saw the largest growth in margins in Q1.
Q:Can you provide comments on the market opportunity for laser hair removal?
A:I’m not 100% sure of the total size of the market, but it is large and growing. We have interest from large companies, and our study will show that we are the best and most cost-effective option.
Q:Can you discuss the magnitude of inventory build for Silly George?
A:We built inventory during the quarter, particularly on the pop-on lashes, which is our most popular product.
Q:What is your baseline runway run rate for AbbVie revenues?
A:AbbVie had an aggressive plan to get 900 machines a year out, but there have been delays in the launch.
Q:Is there a seasonal improvement expected for Silly George?
A:Yes, we expect seasonal growth moving into Q3 and Q4, along with new product launches.
Q:What do you think you’ll be able to survive on the current cash reserves until you’re EBITDA positive?
A:We believe we can survive on current cash reserves, but we are always looking for purchase opportunities.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the total size of the market for laser hair removal, stating, "I’m not 100% sure as to the total size of the market." Additionally, there was a lack of clarity on the baseline runway run rate for AbbVie revenues, with management discussing aggressive plans but not providing specific figures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AbbVie launch
AbbVie shot
China
EBITA loss
Histasolv
Inc expectation
Kenkoderm factor
Medagel Kenkoderm
Medagel product
Mr today
NEXGEL Financial
NEXGEL Inc
NEXGEL supplier
RESONIC machine
Reconciliations non
STADA
SilverSeal AbbVie
SilverSeal wound
Transcript NEXGEL
USmade gel
addition low
advantage manufacturer
brand Medagel
care product
cost good
date
expectation afternoon
factor Medagel
guideline optic
hand product
interest
manufacturing consumer
news
plenty inventory
tariff
NXGL Transcript
NEXGEL, Inc. (NXGL) Q1 2026 Earnings Call Transcript
Positive5-15
The earnings call highlighted a 25% YoY revenue increase, improved gross margins, and a shift from net loss to net income, indicating strong financial performance. Despite the lack of specific strategic guidance, the integration of the acquisition seems to be progressing well. The absence of risk discussion and unclear Q&A responses may slightly temper enthusiasm, but the overall financial health and operational efficiencies suggest a positive sentiment, likely leading to a 2% to 8% stock price increase.
NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call presents a mixed outlook. Financial performance is stable with improved margins and narrowed losses, but logistical delays and dependence on key partnerships pose risks. The Q&A reveals uncertainties, particularly with AbbVie and logistical challenges, dampening optimism. The reaffirmed guidance and potential positive EBITDA are countered by economic uncertainties and cash flow challenges. Without a clear market cap, the sentiment remains neutral, balancing positive operational efficiencies against logistical and partnership risks.
NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call summary and Q&A section reveal strong financial performance, with 121% revenue growth and positive developments in consumer products. Strategic partnerships with major companies like AbbVie suggest future revenue potential despite delays. The company maintains guidance and expects cash flow positivity, indicating financial health. Although there are some uncertainties, like the AbbVie timeline and tariff impacts, the overall sentiment is positive, especially with strong sales from Silly George and new product launches. The positive sentiment outweighs the negatives, suggesting a likely positive stock price movement.
NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Call Transcript
Positive5-15
The earnings call indicates strong financial performance with a 121% revenue increase and improved margins. Despite ongoing challenges like supply chain issues and potential tariff impacts, the company shows resilience with strategic plans to mitigate risks. The Q&A reveals optimism about growth and product launches, though some uncertainties remain. The absence of a shareholder return plan is a minor drawback. Overall, the positive revenue growth, strategic partnerships, and improved financial health suggest a positive stock price movement in the short term.
NXGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
